PL201586A1 - Sposob wytwarzania nowych zwiazkow spiro-hydantionowych - Google Patents

Sposob wytwarzania nowych zwiazkow spiro-hydantionowych

Info

Publication number
PL201586A1
PL201586A1 PL20158677A PL20158677A PL201586A1 PL 201586 A1 PL201586 A1 PL 201586A1 PL 20158677 A PL20158677 A PL 20158677A PL 20158677 A PL20158677 A PL 20158677A PL 201586 A1 PL201586 A1 PL 201586A1
Authority
PL
Poland
Prior art keywords
hydantion
compounds
making new
new spiro
spiro
Prior art date
Application number
PL20158677A
Other languages
English (en)
Other versions
PL108339B1 (en
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of PL201586A1 publication Critical patent/PL201586A1/pl
Publication of PL108339B1 publication Critical patent/PL108339B1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL1977201586A 1976-10-18 1977-10-18 Method of producing new spiro-hydantoin compounds PL108339B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US73306276A 1976-10-18 1976-10-18

Publications (2)

Publication Number Publication Date
PL201586A1 true PL201586A1 (pl) 1978-09-25
PL108339B1 PL108339B1 (en) 1980-04-30

Family

ID=24946075

Family Applications (1)

Application Number Title Priority Date Filing Date
PL1977201586A PL108339B1 (en) 1976-10-18 1977-10-18 Method of producing new spiro-hydantoin compounds

Country Status (8)

Country Link
US (1) US4117230A (pl)
BE (1) BE859824A (pl)
CS (1) CS199690B2 (pl)
HU (1) HU177716B (pl)
IN (1) IN147056B (pl)
PL (1) PL108339B1 (pl)
SU (1) SU741795A3 (pl)
ZA (1) ZA775907B (pl)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4147797A (en) * 1978-08-11 1979-04-03 Pfizer Inc. Spiro-furanohydantoin derivatives
US4181728A (en) * 1978-11-16 1980-01-01 Pfizer Inc. Spiro-polycyclicimidazolidinedione derivatives
US4176185A (en) * 1979-01-22 1979-11-27 Pfizer Inc. Spiro-quinolylhydantoins
US4181729A (en) * 1979-03-21 1980-01-01 Pfizer Inc. Phenyl or phenoxy substituted spiro-imidazolidinedione derivatives
US4193996A (en) * 1979-04-04 1980-03-18 Pfizer Inc. Spiro-quinolone hydantoins
US4210667A (en) * 1979-04-19 1980-07-01 Pfizer Inc. Pharmaceutical preparations containing coumarin carboxylic acid derivatives
AU532110B2 (en) * 1979-11-13 1983-09-15 Ici Ltd. Spiro(imidazolidine-4,3:-indoline)-2,2:5-trione derivatives
US4248882A (en) * 1980-02-12 1981-02-03 Pfizer Inc. Treating diabetes-associated complications with hydantoin amines
US4348526A (en) * 1980-03-28 1982-09-07 Pfizer Inc. Intermediates in the preparation of chiral hydantoins
US4286098A (en) * 1980-03-28 1981-08-25 Pfizer Inc. Process for the preparation of chiral hydantoins
JPS5745185A (en) * 1980-07-21 1982-03-13 Eisai Co Ltd Hydantoin derivative and its preparation
IE53102B1 (en) * 1981-05-12 1988-06-22 Ici Plc Pharmaceutical spiro-succinimide derivatives
ATE10940T1 (de) * 1981-05-12 1985-01-15 Imperial Chemical Industries Plc Pyrrolderivate.
IE52879B1 (en) * 1981-05-12 1988-03-30 Ici Plc Pharmaceutical spiro-hydantoin derivatives
ATE11781T1 (de) * 1981-05-13 1985-02-15 Imperial Chemical Industries Plc Pharmazeutische zubereitungen, die spirosuccinimidderivate enthalten.
US4419521A (en) * 1981-11-12 1983-12-06 Pfizer Inc. 6-Halo-4-chromanamines useful as intermediates to make chiral hydantoins
IL68314A0 (en) * 1982-04-15 1983-07-31 Alcon Lab Inc Method and composition for inhibiting aldose reductase activity and process for preparing spirofluorofluoren and spiro-difluorofluoren compounds
US4436745A (en) 1982-04-15 1984-03-13 Alcon Laboratories, Inc. Method of inhibiting aldose reductase activity
US4540700A (en) * 1982-04-15 1985-09-10 Alcon Laboratories, Inc. Treatment of diabetic complications with certain spiro-imidazolidine-diones
US4464385A (en) * 1982-04-15 1984-08-07 Alcon Laboratories, Inc. Treatment of diabetic complications with hydantoins
US4438272A (en) 1982-04-15 1984-03-20 Alcon Laboratories, Inc. Spiro-(fluoren-9,4'-imidazolidine)-2',5'-diones
US4528387A (en) * 1982-11-10 1985-07-09 Pfizer Inc. Sorbinil by optical resolution of precursor 6-fluoro-4-ureidochroman-4-carboxylic acid
US4556670A (en) * 1982-12-06 1985-12-03 Pfizer Inc. Spiro-3-hetero-azolones for treatment of diabetic complications
US4474967A (en) * 1983-04-27 1984-10-02 Pfizer Inc. 8-Deutero and 8-tritio-substituted derivatives of D-4S-6-fluoro-spiro-[chroman-4,4'-imidazolidine]-2',5'-dione
US5153211A (en) * 1983-09-14 1992-10-06 Alcon Laboratories, Inc. Spiro-tricyclicaromatic succinimide derivatives as inhibitors of aldose reductase
US4537892A (en) * 1983-09-14 1985-08-27 Alcon Laboratories, Inc. Spiro-tricyclicaromatic succinimide derivatives as inhibitors of aldose reductase
EP0136143B1 (en) * 1983-09-23 1987-11-04 Pfizer Inc. Spiro-succinimides for treatment of diabetes complications
US4766141A (en) * 1983-09-23 1988-08-23 Pfizer Inc. Spiro-succinimides for treatment of diabetes complications
DE3561198D1 (en) * 1984-03-23 1988-01-28 Pfizer Spiro-indenes and spiro-1,2-dihydro-naphthalenes for treatment of diabetic complications
US4717725A (en) * 1984-04-11 1988-01-05 Alcon Laboratories, Inc. Ophthalmic wound healing with aldose reductase inhibitors
US4600717A (en) * 1984-04-11 1986-07-15 Alcon Laboratories, Inc. Aldose reductase inhibitors useful in ophthalmic wound healing
JPH06772B2 (ja) * 1984-07-09 1994-01-05 鐘淵化学工業株式会社 ３―（４―フルオロフエノキシ）プロピオニトリルを用いる６―フルオロ―４―クロマノンの製造法
HU198212B (en) * 1984-07-20 1989-08-28 Pfizer Process for production of spiro-imidasolones
EP0172719B1 (en) * 1984-08-20 1988-09-21 Pfizer Inc. Process for the production as asymmetric hydantoins
US4620019A (en) * 1984-08-23 1986-10-28 Pfizer Inc. S-6-fluoro-4-aminochroman-4-carboxylic acid derivatives useful as intermediates for sorbinil
US4609663A (en) * 1984-09-11 1986-09-02 Alcon Laboratories, Inc. Aldose reductase inhibitors useful in glaucoma therapy
US4551542A (en) * 1984-09-26 1985-11-05 Pfizer Inc. Regeneration of 6-fluoro-4-chromanone from 6-fluoro-4-ureidochroman-4-carboxylic acid
US5066659A (en) * 1984-10-30 1991-11-19 Pfizer Inc. Spiro-heteroazalones for treatment of diabetic complications
US4575507A (en) 1985-05-29 1986-03-11 Pfizer Inc. Spiro-imidazolidines as aldose reductase inhibitors and their pharmaceutical use
US4762839A (en) * 1985-06-06 1988-08-09 Tanabe Seiyaku Co., Ltd. Quinazolinone copmpounds useful for the prophyloxis and treatment of diabetic complications
WO1986007353A1 (en) 1985-06-14 1986-12-18 Pfizer Inc. Intermediate in the production of an asymmetric hydantoin
HU206618B (en) * 1986-01-17 1992-12-28 Pfizer Process for producing hydroxyacetic acid derivatives for treating complications of diabetes and pharmaceutical compositions containing them
US4853401A (en) * 1987-04-01 1989-08-01 G. D. Searle & Co. Spiro-hydantoins as aldose reductase inhibitors
US4841079A (en) * 1987-08-07 1989-06-20 Pfizer, Inc. Process for the production of asymmetric hydantoins
US4952694A (en) * 1988-07-27 1990-08-28 Pfizer Inc. Novel resolution process for racemic spiro-hydantoins
US5006657A (en) * 1988-07-27 1991-04-09 Pfizer Inc. Intermediates in a resolution process for racemic spiro hydantoins
US4980357A (en) * 1990-03-01 1990-12-25 Pfizer Inc. Azolidinedione derivatives
US5151544A (en) * 1990-05-25 1992-09-29 Alcon Laboratories, Inc. Intermediates in the preparation of chiral spirofluorenehydantoins
GB2355264A (en) 1999-09-30 2001-04-18 Merck & Co Inc Spirohydantoin derivatives useful as alpha 1a adrenoceptor antagonists

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2716648A (en) * 1955-08-30 Hydantoin derivatives
US2683718A (en) * 1952-01-11 1954-07-13 Searle & Co Spiro-[xanthene-9, 4'-imidazolidine]-2, 5-dione
DE1135915B (de) * 1961-06-29 1962-09-06 Asta Werke Ag Chem Fab Verfahren zur Herstellung neuer, antikonvulsiv wirksamer Spirohydantoine
US3532744A (en) * 1967-07-28 1970-10-06 American Home Prod 1- and 2-amino substituted indane and tetralene carboxylic acids

Also Published As

Publication number Publication date
SU741795A3 (ru) 1980-06-15
ZA775907B (en) 1978-05-30
US4117230A (en) 1978-09-26
PL108339B1 (en) 1980-04-30
IN147056B (pl) 1979-10-27
BE859824A (fr) 1978-04-17
HU177716B (en) 1981-12-28
CS199690B2 (cs) 1980-07-31

Similar Documents

Publication Publication Date Title
PL201586A1 (pl) Sposob wytwarzania nowych zwiazkow spiro-hydantionowych
PL196505A1 (pl) Sposob wytwarzania nowych zwiazkow aminoalkiloheterocyklicznych
PL201286A1 (pl) Sposob wytwarzania nowych 1-aryloksy-2-hydroksy-3-alkileno-aminopropanow
PL200289A1 (pl) Sposob wytwarzania zwiazkow 3-chlorocefemowych
PL199798A1 (pl) Sposob wytwarzania gamma-pironow
PL201837A1 (pl) Sposob wytwarzania zwiazkow cynoorganicznych
PL199298A1 (pl) Sposob wytwarzania 2-bromo-6-fluoro-n-2-imidazolidynylideno-benzaminy
PL200251A1 (pl) Sposob wytwarzania nowych podstawionych 2-fenyloaminoimidazolin-/2/
PL200534A1 (pl) Sposob wytwarzania nowych oksadeztiacefalosporyn
PL200583A1 (pl) Sposob wytwarzania nowych pochodnych benzopiranu
PL199633A1 (pl) Sposob wytwarzania 5-m-toliloksyuracylu
PL200605A1 (pl) Sposob wytwarzania nowych pochodnych metioninoenkefaliny
PL202091A1 (pl) Sposob wytwarzania gamma-pyronow
PL201133A1 (pl) Sposob wytwarzania nowych pirydobenzodwuazepinonow
PL201839A1 (pl) Sposob wytwarzania zwiazkow cynoorganicznych
PL202660A1 (pl) Sposob wytwarzania nowych pochodnych spirooksazolidynodionu
PL195267A1 (pl) Sposob wytwarzania(2-ketopirolidyno)-alkanokarbonamidow
PL201161A1 (pl) Sposob wytwarzania nowych pochodnych 9-chloroprednisolonu
PL196061A1 (pl) Sposob wytwarzania nowych pochodnych indolizyny
PL197311A1 (pl) Sposob wytwarzania nowych zwiazkow ketotia
PL201883A1 (pl) Sposob wytwarzania nowych pochodnych trans-5a-arylo-dziesieciowodorobenzazepiny
PL202697A1 (pl) Sposob wytwarzania 2-bromo-alfa-ergokryptyny
PL196543A1 (pl) Sposob wytwarzania nowych pochodnych azyrydyny
PL199191A1 (pl) Sposob wytwarzania nowych glicynoamidow
PL198294A1 (pl) Sposob wytwarzania nowych zwiazkow tiazolowych